A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum

A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum

Currently available platforms to study liver stage of Plasmodium species have limitations. Here, the authors show that primary human hepatocyte cultures in 384-well format support hypnozoite and other liver stage development and are suitable for drug and antibody screens.

Bibliographic Details
Main Authors: Alison Roth, Steven P. Maher, Amy J. Conway, Ratawan Ubalee, Victor Chaumeau, Chiara Andolina, Stephen A. Kaba, Amélie Vantaux, Malina A. Bakowski, Richard Thomson-Luque, Swamy Rakesh Adapa, Naresh Singh, Samantha J. Barnes, Caitlin A. Cooper, Mélanie Rouillier, Case W. McNamara, Sebastian A. Mikolajczak, Noah Sather, Benoît Witkowski, Brice Campo, Stefan H. I. Kappe, David E. Lanar, François Nosten, Silas Davidson, Rays H. Y. Jiang, Dennis E. Kyle, John H. Adams
Format: Article
Language:English
Published: Nature Publishing Group 2018-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-04221-9

Internet

https://doi.org/10.1038/s41467-018-04221-9

Similar Items